Tarsus Pharmaceuticals, Inc.
TARSNASDAQHealthcare● Active
$60.72
+$1.44(+2.43%)
Market Cap$2.6B
P/E Ratio—
52W High$85.25
52W Low$38.51
Tarsus Pharmaceuticals, Inc. (TARS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TARS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.16
Est. -$0.40 · +60.2%
Revenue
$0.16B
Est. $0.15B · +8.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
TARS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.22 | — | — | — | $0.17B | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$0.40 | -$0.16 | +60.2% | $0.16B | $0.15B | +8.3% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -$0.10 | -$0.20 | -94.2% | $0.15B | $0.14B | +4.9% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.35 | -$0.30 | +14.3% | $0.12B | $0.14B | -17.9% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.33 | -$0.48 | -45.5% | $0.10B | $0.11B | -9.2% |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.69 | -$0.64 | +7.3% | $0.08B | $0.10B | -21.0% |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$0.68 | -$0.60 | +11.8% | $0.07B | $0.06B | +3.0% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.94 | -$0.61 | +35.1% | $0.05B | $0.04B | +11.4% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.22
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.40
EPS Surpr.
+60.2%
Revenue
$0.16B
Q1 FY2026
Feb 23, 2026Miss
EPS Actual
-$0.20
EPS Est.
-$0.10
EPS Surpr.
-94.2%
Revenue
$0.15B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.35
EPS Surpr.
+14.3%
Revenue
$0.12B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.48
EPS Est.
-$0.33
EPS Surpr.
-45.5%
Revenue
$0.10B
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.64
EPS Est.
-$0.69
EPS Surpr.
+7.3%
Revenue
$0.08B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$0.60
EPS Est.
-$0.68
EPS Surpr.
+11.8%
Revenue
$0.07B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.61
EPS Est.
-$0.94
EPS Surpr.
+35.1%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.48 | $1.52 | $1.57 | 2 |
| Q3 FY2028 | $1.22 | $1.25 | $1.29 | 2 |
| Q2 FY2028 | $1.11 | $1.14 | $1.18 | 2 |
| Q1 FY2028 | $0.77 | $0.79 | $0.82 | 2 |
| Q4 FY2027 | $0.96 | $0.99 | $1.02 | 1 |
| Q3 FY2027 | $0.69 | $0.71 | $0.73 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.3B | $0.3B | $0.3B | 2 |
| Q3 FY2028 | $0.3B | $0.3B | $0.3B | 2 |
| Q2 FY2028 | $0.3B | $0.3B | $0.3B | 2 |
| Q1 FY2028 | $0.2B | $0.2B | $0.3B | 2 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +60.2% | $65.04 | $64.76 | -0.43% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -94.2% | $66.61 | $69.59 | +4.47% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +14.3% | $69.79 | $71.50 | +2.45% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -45.5% | $41.15 | $41.64 | +1.19% |
| ▲ Q2 FY2025 | May 1, 2025 | +7.3% | $51.91 | $50.30 | -3.10% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +11.8% | $45.54 | $41.29 | -9.33% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +35.1% | $47.57 | $46.51 | -2.23% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +10.2% | $22.69 | $23.61 | +4.05% |
Q2 FY2026-0.43%
Report Date
May 6, 2026
EPS Beat/Miss
+60.2%
Price Before
$65.04
Price After
$64.76
Q1 FY2026+4.47%
Report Date
Feb 23, 2026
EPS Beat/Miss
-94.2%
Price Before
$66.61
Price After
$69.59
Q4 FY2025+2.45%
Report Date
Nov 4, 2025
EPS Beat/Miss
+14.3%
Price Before
$69.79
Price After
$71.50
Q3 FY2025+1.19%
Report Date
Aug 6, 2025
EPS Beat/Miss
-45.5%
Price Before
$41.15
Price After
$41.64
Q2 FY2025-3.10%
Report Date
May 1, 2025
EPS Beat/Miss
+7.3%
Price Before
$51.91
Price After
$50.30
Q1 FY2025-9.33%
Report Date
Feb 25, 2025
EPS Beat/Miss
+11.8%
Price Before
$45.54
Price After
$41.29
Q4 FY2024-2.23%
Report Date
Nov 13, 2024
EPS Beat/Miss
+35.1%
Price Before
$47.57
Price After
$46.51
Q3 FY2024+4.05%
Report Date
Aug 8, 2024
EPS Beat/Miss
+10.2%
Price Before
$22.69
Price After
$23.61
Avg Beat Reaction-1.43%
Avg Miss Reaction+2.83%
Beat Rate6 / 8 quarters
Largest Move-9.33% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TARS ends December
Tarsus Pharmaceuticals, Inc. (TARS) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.16 — beating the analyst consensus of $-0.40 by +60.2%. The next TARS earnings date is expected around September 1, 2026.
Each quarter, investors track TARS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TARS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TARS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TARS earnings · 5 questionsTarsus Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. TARS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TARS historically reports after market close (AMC).
TARS earnings datewhen is TARS earningsTARS next earnings datewhen does TARS report earningsTARS earnings calendar
▸ Source: FMP · Tarsus Pharmaceuticals, Inc. SEC filings · US GAAP · Tarsus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026